English
简体中文
Total: £ 56.28
Published Date: 2026-04-02 | Pages: 118 | Tables: 124 | Pharma & Healthcare
The global Pets Anti-infective Drugs market was valued at US$ 2434 million in 2025 and is anticipated to reach US$ 7185 million by 2032, at a CAGR of 17.0% from 2026 to 2032.
The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on Pets Anti-infective Drugs competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.
Leptospirosis, staphylococcal infection, bacterial ear infection, actinomycosis, and nocardiosis are some of the most common forms of infections in pets. Moreover, pets are susceptible to bacterial diseases, such as plague, brucellosis, and Lyme disease. Anti-infectives is a general term used to describe any medicine that is capable of inhibiting the spread of an organism infectious or by killing the infectious organism outright.This term encompasses antibiotics, antifungals etc.
The pet anti-infective drug market is a growing area. With the expansion of the global pet market and the improvement of pet health awareness, this market has shown great development potential.
The pet anti-infective drug market is dominated by many well-known companies, such as Zoetis, Merck, Elanco, Virbac, Dechra Veterinary Products and Ceva Santé Animale, which have deep technical accumulation and market experience in veterinary drug research and development, production and market operation.
The market concentration is high, and a few companies occupy a large market share, but with the entry of new companies and the intensification of market competition, the market pattern may change.
Pet anti-infective drugs mainly include antibiotics, antibacterial drugs and other types, which are used to prevent and treat various bacterial infections of pets. These drugs play an important role in improving the quality of life of pets and prolonging their lifespan.
With the advancement of science and technology and the increase in R&D investment, new products and new therapies will continue to emerge in the pet anti-infective drug market. These innovative products will have better efficacy, lower side effects and higher safety, meeting the diverse needs of pet owners.
With the development of precision medicine, the pet anti-infective drug market will pay more attention to personalized treatment in the future. Providing customized anti-infection treatment plans for pets of different types, ages, and health conditions will become an important direction for market development.
This report delivers a comprehensive overview of the global Pets Anti-infective Drugs market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Pets Anti-infective Drugs. The Pets Anti-infective Drugs market size, estimates, and forecasts are provided in terms of sales volume (K Units) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Pets Anti-infective Drugs market comprehensively. Regional market sizes by Administration Method, by Application, , and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Pets Anti-infective Drugs manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Administration Method, by Application, and by region.
Market Segmentation
By Company
Zoetis
Merck
Elanco
Virbac
Dechra Veterinary Products
Ceva Santé Animale
Vetoquinol
Nanjing Jindun Animal
Wuhan Chopperlvya
Bimeda Animal Health
Ouro Fino Saude
Norbrook
Hanvet Pet Health
Wuhan Hvsen Biotechnology
Zhejiang Hisun Animal Healthcare Products
Segment by Administration Method
External Use
Internal Use
Injection
by Application
Dog
Cat
Others
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Administration Method, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Provides a detailed analysis of the competitive landscape for Pets Anti-infective Drugs manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
Chapter 3: Examines Pets Anti-infective Drugs sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
Chapter 4: Analyzes segments by Administration Method, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
Chapter 9: Summarizes the key findings and conclusions of the report.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Pets Anti-infective Drugs Market Overview
1.1 Product Definition
1.2 Pets Anti-infective Drugs by Administration Method
1.2.1 Global Pets Anti-infective Drugs Market Value by Administration Method: 2025 vs 2032
1.2.2 External Use
1.2.3 Internal Use
1.2.4 Injection
1.3 Pets Anti-infective Drugs by Application
1.3.1 Global Pets Anti-infective Drugs Market Value by Application: 2025 vs 2032
1.3.2 Dog
1.3.3 Cat
1.3.4 Others
1.4 Global Pets Anti-infective Drugs Market Size Estimates and Forecasts
1.4.1 Global Pets Anti-infective Drugs Revenue 2021–2032
1.4.2 Global Pets Anti-infective Drugs Sales 2021–2032
1.4.3 Global Pets Anti-infective Drugs Market Average Price (2021–2032)
1.5 Assumptions and Limitations
2 Pets Anti-infective Drugs Market Competition by Manufacturers
2.1 Global Pets Anti-infective Drugs Sales Market Share by Manufacturers (2021–2026)
2.2 Global Pets Anti-infective Drugs Revenue Market Share by Manufacturers (2021–2026)
2.3 Global Pets Anti-infective Drugs Average Price by Manufacturers (2021–2026)
2.4 Global Key Players of Pets Anti-infective Drugs, Industry Ranking, 2023 vs 2024 vs 2025
2.5 Global Key Manufacturers of Pets Anti-infective Drugs, Manufacturing Sites and Headquarters
2.6 Global Key Manufacturers of Pets Anti-infective Drugs, Product Types and Applications
2.7 Global Key Manufacturers of Pets Anti-infective Drugs, Date of Entry into the Industry
2.8 Global Pets Anti-infective Drugs Market Competitive Situation and Trends
2.8.1 Global Pets Anti-infective Drugs Market Concentration Rate
2.8.2 The Top 5 and Top 10 Global Pets Anti-infective Drugs Players Market Share by Revenue
2.8.3 Global Pets Anti-infective Drugs Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Pets Anti-infective Drugs Market Scenario by Region
3.1 Global Pets Anti-infective Drugs Market Size by Region: 2021 vs 2025 vs 2032
3.2 Global Pets Anti-infective Drugs Sales by Region: 2021–2032
3.2.1 Global Pets Anti-infective Drugs Sales by Region: 2021–2026
3.2.2 Global Pets Anti-infective Drugs Sales by Region: 2027–2032
3.3 Global Pets Anti-infective Drugs Revenue by Region: 2021–2032
3.3.1 Global Pets Anti-infective Drugs Revenue by Region: 2021–2026
3.3.2 Global Pets Anti-infective Drugs Revenue by Region: 2027–2032
3.4 North America Pets Anti-infective Drugs Market Facts & Figures by Country
3.4.1 North America Pets Anti-infective Drugs Market Size by Country: 2021 vs 2025 vs 2032
3.4.2 North America Pets Anti-infective Drugs Sales by Country (2021–2032)
3.4.3 North America Pets Anti-infective Drugs Revenue by Country (2021–2032)
3.4.4 United States
3.4.5 Canada
3.5 Europe Pets Anti-infective Drugs Market Facts & Figures by Country
3.5.1 Europe Pets Anti-infective Drugs Market Size by Country: 2021 vs 2025 vs 2032
3.5.2 Europe Pets Anti-infective Drugs Sales by Country (2021–2032)
3.5.3 Europe Pets Anti-infective Drugs Revenue by Country (2021–2032)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Pets Anti-infective Drugs Market Facts & Figures by Region
3.6.1 Asia Pacific Pets Anti-infective Drugs Market Size by Region: 2021 vs 2025 vs 2032
3.6.2 Asia Pacific Pets Anti-infective Drugs Sales by Region (2021–2032)
3.6.3 Asia Pacific Pets Anti-infective Drugs Revenue by Region (2021–2032)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Pets Anti-infective Drugs Market Facts & Figures by Country
3.7.1 Latin America Pets Anti-infective Drugs Market Size by Country: 2021 vs 2025 vs 2032
3.7.2 Latin America Pets Anti-infective Drugs Sales by Country (2021–2032)
3.7.3 Latin America Pets Anti-infective Drugs Revenue by Country (2021–2032)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Pets Anti-infective Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa Pets Anti-infective Drugs Market Size by Country: 2021 vs 2025 vs 2032
3.8.2 Middle East and Africa Pets Anti-infective Drugs Sales by Country (2021–2032)
3.8.3 Middle East and Africa Pets Anti-infective Drugs Revenue by Country (2021–2032)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Administration Method
4.1 Global Pets Anti-infective Drugs Sales by Administration Method (2021–2032)
4.1.1 Global Pets Anti-infective Drugs Sales by Administration Method (2021–2026)
4.1.2 Global Pets Anti-infective Drugs Sales by Administration Method (2027–2032)
4.1.3 Global Pets Anti-infective Drugs Sales Market Share by Administration Method (2021–2032)
4.2 Global Pets Anti-infective Drugs Revenue by Administration Method (2021–2032)
4.2.1 Global Pets Anti-infective Drugs Revenue by Administration Method (2021–2026)
4.2.2 Global Pets Anti-infective Drugs Revenue by Administration Method (2027–2032)
4.2.3 Global Pets Anti-infective Drugs Revenue Market Share by Administration Method (2021–2032)
4.3 Global Pets Anti-infective Drugs Price by Administration Method (2021–2032)
5 Segment by Application
5.1 Global Pets Anti-infective Drugs Sales by Application (2021–2032)
5.1.1 Global Pets Anti-infective Drugs Sales by Application (2021–2026)
5.1.2 Global Pets Anti-infective Drugs Sales by Application (2027–2032)
5.1.3 Global Pets Anti-infective Drugs Sales Market Share by Application (2021–2032)
5.2 Global Pets Anti-infective Drugs Revenue by Application (2021–2032)
5.2.1 Global Pets Anti-infective Drugs Revenue by Application (2021–2026)
5.2.2 Global Pets Anti-infective Drugs Revenue by Application (2027–2032)
5.2.3 Global Pets Anti-infective Drugs Revenue Market Share by Application (2021–2032)
5.3 Global Pets Anti-infective Drugs Price by Application (2021–2032)
6 Key Companies Profiled
6.1 Zoetis
6.1.1 Zoetis Company Information
6.1.2 Zoetis Description and Business Overview
6.1.3 Zoetis Pets Anti-infective Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.1.4 Zoetis Pets Anti-infective Drugs Product Portfolio
6.1.5 Zoetis Recent Developments/Updates
6.2 Merck
6.2.1 Merck Company Information
6.2.2 Merck Description and Business Overview
6.2.3 Merck Pets Anti-infective Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.2.4 Merck Pets Anti-infective Drugs Product Portfolio
6.2.5 Merck Recent Developments/Updates
6.3 Elanco
6.3.1 Elanco Company Information
6.3.2 Elanco Description and Business Overview
6.3.3 Elanco Pets Anti-infective Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.3.4 Elanco Pets Anti-infective Drugs Product Portfolio
6.3.5 Elanco Recent Developments/Updates
6.4 Virbac
6.4.1 Virbac Company Information
6.4.2 Virbac Description and Business Overview
6.4.3 Virbac Pets Anti-infective Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.4.4 Virbac Pets Anti-infective Drugs Product Portfolio
6.4.5 Virbac Recent Developments/Updates
6.5 Dechra Veterinary Products
6.5.1 Dechra Veterinary Products Company Information
6.5.2 Dechra Veterinary Products Description and Business Overview
6.5.3 Dechra Veterinary Products Pets Anti-infective Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.5.4 Dechra Veterinary Products Pets Anti-infective Drugs Product Portfolio
6.5.5 Dechra Veterinary Products Recent Developments/Updates
6.6 Ceva Santé Animale
6.6.1 Ceva Santé Animale Company Information
6.6.2 Ceva Santé Animale Description and Business Overview
6.6.3 Ceva Santé Animale Pets Anti-infective Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.6.4 Ceva Santé Animale Pets Anti-infective Drugs Product Portfolio
6.6.5 Ceva Santé Animale Recent Developments/Updates
6.7 Vetoquinol
6.7.1 Vetoquinol Company Information
6.7.2 Vetoquinol Description and Business Overview
6.7.3 Vetoquinol Pets Anti-infective Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.7.4 Vetoquinol Pets Anti-infective Drugs Product Portfolio
6.7.5 Vetoquinol Recent Developments/Updates
6.8 Nanjing Jindun Animal
6.8.1 Nanjing Jindun Animal Company Information
6.8.2 Nanjing Jindun Animal Description and Business Overview
6.8.3 Nanjing Jindun Animal Pets Anti-infective Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.8.4 Nanjing Jindun Animal Pets Anti-infective Drugs Product Portfolio
6.8.5 Nanjing Jindun Animal Recent Developments/Updates
6.9 Wuhan Chopperlvya
6.9.1 Wuhan Chopperlvya Company Information
6.9.2 Wuhan Chopperlvya Description and Business Overview
6.9.3 Wuhan Chopperlvya Pets Anti-infective Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.9.4 Wuhan Chopperlvya Pets Anti-infective Drugs Product Portfolio
6.9.5 Wuhan Chopperlvya Recent Developments/Updates
6.10 Bimeda Animal Health
6.10.1 Bimeda Animal Health Company Information
6.10.2 Bimeda Animal Health Description and Business Overview
6.10.3 Bimeda Animal Health Pets Anti-infective Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.10.4 Bimeda Animal Health Pets Anti-infective Drugs Product Portfolio
6.10.5 Bimeda Animal Health Recent Developments/Updates
6.11 Ouro Fino Saude
6.11.1 Ouro Fino Saude Company Information
6.11.2 Ouro Fino Saude Description and Business Overview
6.11.3 Ouro Fino Saude Pets Anti-infective Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.11.4 Ouro Fino Saude Pets Anti-infective Drugs Product Portfolio
6.11.5 Ouro Fino Saude Recent Developments/Updates
6.12 Norbrook
6.12.1 Norbrook Company Information
6.12.2 Norbrook Description and Business Overview
6.12.3 Norbrook Pets Anti-infective Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.12.4 Norbrook Pets Anti-infective Drugs Product Portfolio
6.12.5 Norbrook Recent Developments/Updates
6.13 Hanvet Pet Health
6.13.1 Hanvet Pet Health Company Information
6.13.2 Hanvet Pet Health Description and Business Overview
6.13.3 Hanvet Pet Health Pets Anti-infective Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.13.4 Hanvet Pet Health Pets Anti-infective Drugs Product Portfolio
6.13.5 Hanvet Pet Health Recent Developments/Updates
6.14 Wuhan Hvsen Biotechnology
6.14.1 Wuhan Hvsen Biotechnology Company Information
6.14.2 Wuhan Hvsen Biotechnology Description and Business Overview
6.14.3 Wuhan Hvsen Biotechnology Pets Anti-infective Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.14.4 Wuhan Hvsen Biotechnology Pets Anti-infective Drugs Product Portfolio
6.14.5 Wuhan Hvsen Biotechnology Recent Developments/Updates
6.15 Zhejiang Hisun Animal Healthcare Products
6.15.1 Zhejiang Hisun Animal Healthcare Products Company Information
6.15.2 Zhejiang Hisun Animal Healthcare Products Description and Business Overview
6.15.3 Zhejiang Hisun Animal Healthcare Products Pets Anti-infective Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.15.4 Zhejiang Hisun Animal Healthcare Products Pets Anti-infective Drugs Product Portfolio
6.15.5 Zhejiang Hisun Animal Healthcare Products Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Pets Anti-infective Drugs Industry Chain Analysis
7.2 Pets Anti-infective Drugs Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Pets Anti-infective Drugs Production Mode & Process Analysis
7.4 Pets Anti-infective Drugs Sales and Marketing
7.4.1 Pets Anti-infective Drugs Sales Channels
7.4.2 Pets Anti-infective Drugs Distributors
7.5 Pets Anti-infective Drugs Customer Analysis
8 Pets Anti-infective Drugs Market Dynamics
8.1 Pets Anti-infective Drugs Industry Trends
8.2 Pets Anti-infective Drugs Market Drivers
8.3 Pets Anti-infective Drugs Market Challenges
8.4 Pets Anti-infective Drugs Market Restraints
8.5 Impact of U.S. Tariffs
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
Table 1. Global Pets Anti-infective Drugs Market Value by Administration Method (US$ Million), 2025 vs 2032
Table 2. Global Pets Anti-infective Drugs Market Value by Application (US$ Million), 2025 vs 2032
Table 3. Global Pets Anti-infective Drugs Market Competitive Situation by Manufacturers in 2025
Table 4. Global Pets Anti-infective Drugs Sales (K Units) of Key Manufacturers (2021–2026)
Table 5. Global Pets Anti-infective Drugs Sales Market Share by Manufacturers (2021–2026)
Table 6. Global Pets Anti-infective Drugs Revenue (US$ Million) by Manufacturers (2021–2026)
Table 7. Global Pets Anti-infective Drugs Revenue Share by Manufacturers (2021–2026)
Table 8. Global Market Pets Anti-infective Drugs Average Price (US$/Unit) of Key Manufacturers (2021–2026)
Table 9. Global Key Players of Pets Anti-infective Drugs, Industry Ranking, 2023 vs 2024 vs 2025
Table 10. Global Key Manufacturers of Pets Anti-infective Drugs, Manufacturing Sites and Headquarters
Table 11. Global Key Manufacturers of Pets Anti-infective Drugs, Product Types and Applications
Table 12. Global Key Manufacturers of Pets Anti-infective Drugs, Date of Entry into the Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Pets Anti-infective Drugs Companies by Tier (Tier 1, Tier 2, Tier 3), based on Pets Anti-infective Drugs Revenue, 2025
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Pets Anti-infective Drugs Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 17. Global Pets Anti-infective Drugs Sales by Region (K Units), 2021–2026
Table 18. Global Pets Anti-infective Drugs Sales Market Share by Region (2021–2026)
Table 19. Global Pets Anti-infective Drugs Sales by Region (K Units), 2027–2032
Table 20. Global Pets Anti-infective Drugs Sales Market Share by Region (2027–2032)
Table 21. Global Pets Anti-infective Drugs Revenue by Region (US$ Million), 2021–2026
Table 22. Global Pets Anti-infective Drugs Revenue Market Share by Region (2021–2026)
Table 23. Global Pets Anti-infective Drugs Revenue by Region (US$ Million), 2027–2032
Table 24. Global Pets Anti-infective Drugs Revenue Market Share by Region (2027–2032)
Table 25. North America Pets Anti-infective Drugs Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 26. North America Pets Anti-infective Drugs Sales by Country (K Units), 2021–2026
Table 27. North America Pets Anti-infective Drugs Sales by Country (K Units), 2027–2032
Table 28. North America Pets Anti-infective Drugs Revenue by Country (US$ Million), 2021–2026
Table 29. North America Pets Anti-infective Drugs Revenue by Country (US$ Million), 2027–2032
Table 30. Europe Pets Anti-infective Drugs Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 31. Europe Pets Anti-infective Drugs Sales by Country (K Units), 2021–2026
Table 32. Europe Pets Anti-infective Drugs Sales by Country (K Units), 2027–2032
Table 33. Europe Pets Anti-infective Drugs Revenue by Country (US$ Million), 2021–2026
Table 34. Europe Pets Anti-infective Drugs Revenue by Country (US$ Million), 2027–2032
Table 35. Asia Pacific Pets Anti-infective Drugs Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Asia Pacific Pets Anti-infective Drugs Sales by Region (K Units), 2021–2026
Table 37. Asia Pacific Pets Anti-infective Drugs Sales by Region (K Units), 2027–2032
Table 38. Asia Pacific Pets Anti-infective Drugs Revenue by Region (US$ Million), 2021–2026
Table 39. Asia Pacific Pets Anti-infective Drugs Revenue by Region (US$ Million), 2027–2032
Table 40. Latin America Pets Anti-infective Drugs Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 41. Latin America Pets Anti-infective Drugs Sales by Country (K Units), 2021–2026
Table 42. Latin America Pets Anti-infective Drugs Sales by Country (K Units), 2027–2032
Table 43. Latin America Pets Anti-infective Drugs Revenue by Country (US$ Million), 2021–2026
Table 44. Latin America Pets Anti-infective Drugs Revenue by Country (US$ Million), 2027–2032
Table 45. Middle East and Africa Pets Anti-infective Drugs Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 46. Middle East and Africa Pets Anti-infective Drugs Sales by Country (K Units), 2021–2026
Table 47. Middle East and Africa Pets Anti-infective Drugs Sales by Country (K Units), 2027–2032
Table 48. Middle East and Africa Pets Anti-infective Drugs Revenue by Country (US$ Million), 2021–2026
Table 49. Middle East and Africa Pets Anti-infective Drugs Revenue by Country (US$ Million), 2027–2032
Table 50. Global Pets Anti-infective Drugs Sales (K Units) by Administration Method (2021–2026)
Table 51. Global Pets Anti-infective Drugs Sales (K Units) by Administration Method (2027–2032)
Table 52. Global Pets Anti-infective Drugs Sales Market Share by Administration Method (2021–2026)
Table 53. Global Pets Anti-infective Drugs Sales Market Share by Administration Method (2027–2032)
Table 54. Global Pets Anti-infective Drugs Revenue (US$ Million) by Administration Method (2021–2026)
Table 55. Global Pets Anti-infective Drugs Revenue (US$ Million) by Administration Method (2027–2032)
Table 56. Global Pets Anti-infective Drugs Revenue Market Share by Administration Method (2021–2026)
Table 57. Global Pets Anti-infective Drugs Revenue Market Share by Administration Method (2027–2032)
Table 58. Global Pets Anti-infective Drugs Price (US$/Unit) by Administration Method (2021–2026)
Table 59. Global Pets Anti-infective Drugs Price (US$/Unit) by Administration Method (2027–2032)
Table 60. Global Pets Anti-infective Drugs Sales (K Units) by Application (2021–2026)
Table 61. Global Pets Anti-infective Drugs Sales (K Units) by Application (2027–2032)
Table 62. Global Pets Anti-infective Drugs Sales Market Share by Application (2021–2026)
Table 63. Global Pets Anti-infective Drugs Sales Market Share by Application (2027–2032)
Table 64. Global Pets Anti-infective Drugs Revenue (US$ Million) by Application (2021–2026)
Table 65. Global Pets Anti-infective Drugs Revenue (US$ Million) by Application (2027–2032)
Table 66. Global Pets Anti-infective Drugs Revenue Market Share by Application (2021–2026)
Table 67. Global Pets Anti-infective Drugs Revenue Market Share by Application (2027–2032)
Table 68. Global Pets Anti-infective Drugs Price (US$/Unit) by Application (2021–2026)
Table 69. Global Pets Anti-infective Drugs Price (US$/Unit) by Application (2027–2032)
Table 70. Zoetis Company Information
Table 71. Zoetis Description and Business Overview
Table 72. Zoetis Pets Anti-infective Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 73. Zoetis Pets Anti-infective Drugs Product
Table 74. Zoetis Recent Developments/Updates
Table 75. Merck Company Information
Table 76. Merck Description and Business Overview
Table 77. Merck Pets Anti-infective Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 78. Merck Pets Anti-infective Drugs Product
Table 79. Merck Recent Developments/Updates
Table 80. Elanco Company Information
Table 81. Elanco Description and Business Overview
Table 82. Elanco Pets Anti-infective Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 83. Elanco Pets Anti-infective Drugs Product
Table 84. Elanco Recent Developments/Updates
Table 85. Virbac Company Information
Table 86. Virbac Description and Business Overview
Table 87. Virbac Pets Anti-infective Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 88. Virbac Pets Anti-infective Drugs Product
Table 89. Virbac Recent Developments/Updates
Table 90. Dechra Veterinary Products Company Information
Table 91. Dechra Veterinary Products Description and Business Overview
Table 92. Dechra Veterinary Products Pets Anti-infective Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 93. Dechra Veterinary Products Pets Anti-infective Drugs Product
Table 94. Dechra Veterinary Products Recent Developments/Updates
Table 95. Ceva Santé Animale Company Information
Table 96. Ceva Santé Animale Description and Business Overview
Table 97. Ceva Santé Animale Pets Anti-infective Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 98. Ceva Santé Animale Pets Anti-infective Drugs Product
Table 99. Ceva Santé Animale Recent Developments/Updates
Table 100. Vetoquinol Company Information
Table 101. Vetoquinol Description and Business Overview
Table 102. Vetoquinol Pets Anti-infective Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 103. Vetoquinol Pets Anti-infective Drugs Product
Table 104. Vetoquinol Recent Developments/Updates
Table 105. Nanjing Jindun Animal Company Information
Table 106. Nanjing Jindun Animal Description and Business Overview
Table 107. Nanjing Jindun Animal Pets Anti-infective Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 108. Nanjing Jindun Animal Pets Anti-infective Drugs Product
Table 109. Nanjing Jindun Animal Recent Developments/Updates
Table 110. Wuhan Chopperlvya Company Information
Table 111. Wuhan Chopperlvya Description and Business Overview
Table 112. Wuhan Chopperlvya Pets Anti-infective Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 113. Wuhan Chopperlvya Pets Anti-infective Drugs Product
Table 114. Wuhan Chopperlvya Recent Developments/Updates
Table 115. Bimeda Animal Health Company Information
Table 116. Bimeda Animal Health Description and Business Overview
Table 117. Bimeda Animal Health Pets Anti-infective Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 118. Bimeda Animal Health Pets Anti-infective Drugs Product
Table 119. Bimeda Animal Health Recent Developments/Updates
Table 120. Ouro Fino Saude Company Information
Table 121. Ouro Fino Saude Description and Business Overview
Table 122. Ouro Fino Saude Pets Anti-infective Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 123. Ouro Fino Saude Pets Anti-infective Drugs Product
Table 124. Ouro Fino Saude Recent Developments/Updates
Table 125. Norbrook Company Information
Table 126. Norbrook Description and Business Overview
Table 127. Norbrook Pets Anti-infective Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 128. Norbrook Pets Anti-infective Drugs Product
Table 129. Norbrook Recent Developments/Updates
Table 130. Hanvet Pet Health Company Information
Table 131. Hanvet Pet Health Description and Business Overview
Table 132. Hanvet Pet Health Pets Anti-infective Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 133. Hanvet Pet Health Pets Anti-infective Drugs Product
Table 134. Hanvet Pet Health Recent Developments/Updates
Table 135. Wuhan Hvsen Biotechnology Company Information
Table 136. Wuhan Hvsen Biotechnology Description and Business Overview
Table 137. Wuhan Hvsen Biotechnology Pets Anti-infective Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 138. Wuhan Hvsen Biotechnology Pets Anti-infective Drugs Product
Table 139. Wuhan Hvsen Biotechnology Recent Developments/Updates
Table 140. Zhejiang Hisun Animal Healthcare Products Company Information
Table 141. Zhejiang Hisun Animal Healthcare Products Description and Business Overview
Table 142. Zhejiang Hisun Animal Healthcare Products Pets Anti-infective Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 143. Zhejiang Hisun Animal Healthcare Products Pets Anti-infective Drugs Product
Table 144. Zhejiang Hisun Animal Healthcare Products Recent Developments/Updates
Table 145. Key Raw Materials Lists
Table 146. Raw Materials Key Suppliers Lists
Table 147. Pets Anti-infective Drugs Distributors List
Table 148. Pets Anti-infective Drugs Customers List
Table 149. Pets Anti-infective Drugs Market Trends
Table 150. Pets Anti-infective Drugs Market Drivers
Table 151. Pets Anti-infective Drugs Market Challenges
Table 152. Pets Anti-infective Drugs Market Restraints
Table 153. Research Programs/Design for This Report
Table 154. Key Data Information from Secondary Sources
Table 155. Key Data Information from Primary Sources
Table 156. Authors List of This Report
List of Figures
Figure 1. Product Picture of Pets Anti-infective Drugs
Figure 2. Global Pets Anti-infective Drugs Market Value by Administration Method (US$ Million), 2021–2032
Figure 3. Global Pets Anti-infective Drugs Market Share by Administration Method: 2025 & 2032
Figure 4. External Use Product Picture
Figure 5. Internal Use Product Picture
Figure 6. Injection Product Picture
Figure 7. Global Pets Anti-infective Drugs Market Value by Application (US$ Million), 2021–2032
Figure 8. Global Pets Anti-infective Drugs Market Share by Application: 2025 & 2032
Figure 9. Dog
Figure 10. Cat
Figure 11. Others
Figure 12. Global Pets Anti-infective Drugs Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 13. Global Pets Anti-infective Drugs Market Size (US$ Million), 2021–2032
Figure 14. Global Pets Anti-infective Drugs Sales (K Units), 2021–2032
Figure 15. Global Pets Anti-infective Drugs Average Price (US$/Unit), 2021–2032
Figure 16. Pets Anti-infective Drugs Report Years Considered
Figure 17. Pets Anti-infective Drugs Sales Share by Manufacturers in 2025
Figure 18. Global Pets Anti-infective Drugs Revenue Share by Manufacturers in 2025
Figure 19. Top 5 and Top 10 Global Pets Anti-infective Drugs Players: Market Share by Revenue in Pets Anti-infective Drugs in 2025
Figure 20. Pets Anti-infective Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
Figure 21. Global Pets Anti-infective Drugs Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Figure 22. North America Pets Anti-infective Drugs Sales Market Share by Country (2021–2032)
Figure 23. North America Pets Anti-infective Drugs Revenue Market Share by Country (2021–2032)
Figure 24. United States Pets Anti-infective Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 25. Canada Pets Anti-infective Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 26. Europe Pets Anti-infective Drugs Sales Market Share by Country (2021–2032)
Figure 27. Europe Pets Anti-infective Drugs Revenue Market Share by Country (2021–2032)
Figure 28. Germany Pets Anti-infective Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 29. France Pets Anti-infective Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 30. U.K. Pets Anti-infective Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 31. Italy Pets Anti-infective Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 32. Russia Pets Anti-infective Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 33. Asia Pacific Pets Anti-infective Drugs Sales Market Share by Region (2021–2032)
Figure 34. Asia Pacific Pets Anti-infective Drugs Revenue Market Share by Region (2021–2032)
Figure 35. China Pets Anti-infective Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 36. Japan Pets Anti-infective Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 37. South Korea Pets Anti-infective Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 38. India Pets Anti-infective Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 39. Australia Pets Anti-infective Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 40. China Taiwan Pets Anti-infective Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 41. Indonesia Pets Anti-infective Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 42. Thailand Pets Anti-infective Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 43. Malaysia Pets Anti-infective Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 44. Latin America Pets Anti-infective Drugs Sales Market Share by Country (2021–2032)
Figure 45. Latin America Pets Anti-infective Drugs Revenue Market Share by Country (2021–2032)
Figure 46. Mexico Pets Anti-infective Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 47. Brazil Pets Anti-infective Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 48. Argentina Pets Anti-infective Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 49. Middle East and Africa Pets Anti-infective Drugs Sales Market Share by Country (2021–2032)
Figure 50. Middle East and Africa Pets Anti-infective Drugs Revenue Market Share by Country (2021–2032)
Figure 51. Turkey Pets Anti-infective Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 52. Saudi Arabia Pets Anti-infective Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 53. UAE Pets Anti-infective Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 54. Global Sales Market Share of Pets Anti-infective Drugs by Administration Method (2021–2032)
Figure 55. Global Revenue Market Share of Pets Anti-infective Drugs by Administration Method (2021–2032)
Figure 56. Global Pets Anti-infective Drugs Price (US$/Unit) by Administration Method (2021–2032)
Figure 57. Global Sales Market Share of Pets Anti-infective Drugs by Application (2021–2032)
Figure 58. Global Revenue Market Share of Pets Anti-infective Drugs by Application (2021–2032)
Figure 59. Global Pets Anti-infective Drugs Price (US$/Unit) by Application (2021–2032)
Figure 60. Pets Anti-infective Drugs Value Chain
Figure 61. Channels of Distribution (Direct Vs Distribution)
Figure 62. Bottom-up and Top-down Approaches for This Report
Figure 63. Data Triangulation
Figure 64. Key Executives Interviewed
